CTSO - シトソ―ベンツ （Cytosorbents Corporation） シトソ―ベンツCTSOのチャート
CTSOの企業情報
| symbol | CTSO |
|---|---|
| 会社名 | Cytosorbents Corp （シトソ―ベンツ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product CytoSorb which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation organ failure and death in common critical illnesses such as sepsis burn injury trauma lung injury and pancreatitis. In addition CytoSorb is used in other inflammatory conditions such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology including HemoDefend ContrastSorb DrugSorb BetaSorb and others. シトソ―ベンツは、免疫療法に特化した米国の医療会社。多臓器不全を治療するために炎症を調節する血液浄化技術プラットフォ―ムを使用して免疫療法を行う。欧州連合で、体外サイトカインフィルタ｢CytoSorb｣デバイスを販売する｡また血液浄化システム｢HomoDefend｣と血液から有毒な薬を取り除く｢DrugSorb｣を開発する。 CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 66 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorb® has been used in more than 110,000 human treatments to date. CytoSorb has received CE-Mark label expansions for the removal of bilirubin (liver disease), myoglobin (trauma) and both ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in critically ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances. CytoSorb has also been granted FDA Breakthrough Designation for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery. CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than $38 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and multiple applications pending, including ECOS-300CY™, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ™, K+ontrol™, ContrastSorb, DrugSorb, and others. |
| 本社所在地 | 7 Deer Park Drive Suite K Monmouth Junction NJ 08852 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | 37347 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 84人 |
| url | www.cytosorbents.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ctso |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -13.01103 |
| 終値（lastsale） | 11.61 |
| 時価総額（marketcap） | 365244133.23 |
| 時価総額 | 時価総額（百万ドル） 360.83980 |
| 売上高 | 売上高（百万ドル） 19.15110 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 345.45086 |
| 当期純利益 | 当期純利益（百万ドル） -14.00454 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cytosorbents Corp revenues increased 60% to $10.7M. Net loss increased from $3.3M to $8.8M. Revenues reflect CytoSorb sales increase of 71% to $9.6M Other sales increase from $14K to $88K. Higher net loss reflects General and administrative -other increase of 49% to $7.8M (expense) Stock-based Compensation in SGA increase from $876K to $2.5M (expense). |
CTSOのテクニカル分析
CTSOのニュース
CytoSorbents Earnings Preview 2023/03/08 14:01:51 Benzinga
CytoSorbents (NASDAQ: CTSO ) is set to give its latest quarterly earnings report on Thursday, 2023-03-09. Here''s what investors need to know before the announcement. Analysts estimate that CytoSorbents will report an earnings per share (EPS) of $-0.17. CytoSorbents bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next … Full story available on Benzinga.com
CytoSorbents to Present at the Cowen 43rd Annual Health Care Conference 2023/02/27 12:00:00 PR Newswire
PRINCETON, N.J., Feb. 27, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan, Chief Executive Officer, will present…
CytoSorbents to Report Fiscal 2022 Operating and Financial Results 2023/02/24 12:00:00 PR Newswire
MONMOUTH JUNCTION, N.J., Feb. 24, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fiscal 2022 financial results on Thursday, March 9,…
Cytosorbents Corporation (CTSO) will benefit from these strategies 2023/02/07 13:48:00 US Post News
The share price of Cytosorbents Corporation (NASDAQ:CTSO) rose to $4.17 per share on Monday from $3.56. While Cytosorbents Corporation has overperformed by 17.13%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CTSO rose by 12.70%, with highs and lows ranging from $4.15 to $1.03, whereas the […]
CytoSorbents guides Q4 revenue above estimates 2023/01/31 13:03:30 Seeking Alpha
Medical device company CytoSorbents (CTSO) reported on Tuesday its preliminary results, expecting total revenue of ~$34.7M (consensus: $33.57M) for 2022.The company generated $43.2M in…
CytoSorbents CFO to retire 2022/10/07 11:24:00 Seeking Alpha
CytoSorbents (CTSO) CFO Kathleen Bloch plans to retire on Mar. 31, 2023.
CytoSorbents secures $4.3M contract by U.S. Department of Defense 2022/10/06 11:27:04 Seeking Alpha
CytoSorbents (CTSO) notifies that the U.S. Army Medical Research Acquisition Activity has awarded the company a three-year Phase III contract valued at $4,292,641 to enable…
CytoSorbents Awarded an Approximately $4.3M Contract by the U.S. Department of Defense to Develop HemoDefend-BGA™ for Freeze-Dried Universal Plasma 2022/10/06 11:00:00 Benzinga
PRINCETON, N.J. , Oct. 6, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO ), a critical care immunotherapy leader specializing in blood purification, announced today that the U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded the Company a three-year Phase III contract valued at $4,292,641 to customize the design of the HemoDefend-BGA™ filter for sterile integration into collections systems for freeze-dried plasma processing to generate freeze-dried universal plasma. Without the need for blood typing, widespread availability of universal plasma could help save lives via faster emergency treatment in both civilian and military settings. CTSO ) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents'' flagship product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is conducting trials to support FDA marketing approval of DrugSorb™-ATR for antithrombotic drug removal during cardiothoracic surgery. (PRNewsfoto/CytoSorbents Corporation)" alt="CytoSorbents Corporation (NASDAQ: CTSO ) is a leader in the treatment of life-threatening conditions using blood purification.
CytoSorbents Achieves ISO 13485 Certification of Princeton Manufacturing Facility in New Jersey 2022/09/27 12:21:00 PR Newswire
CytoSorb®, DrugSorb®-ATR, and ECOS-300CY® now cleared for manufacturing from this site PRINCETON, N.J., Sept. 27, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using…
CytoSorbents stock rises on US DoD contract to develop device for universal plasma 2022/09/09 12:02:19 Seeking Alpha
CytoSorbents (CTSO) said it has received a two-year grant of ~$1.977M from the U.S. Department of Defense to help develop HemoDefend-BGA adsorber to a fully-finished commercial…
CytoSorbents Corporation (CTSO) CEO Phillip Chan on Q3 2021 Results - Earnings Call Transcript 2021/11/07 04:57:44 Seeking Alpha
CytoSorbents Reports Full Third Quarter 2021 Financial and Operational Results 2021/11/04 20:15:00 PR Newswire
MONMOUTH JUNCTION, N.J., Nov. 4, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, reports full
Blood Purification Equipment Market Report, Size 2021: Global Trends, Top Players Updates, Future Plans, Industry Impact and Forecast till 2027 | Cytosorbents Corporation, Baxter International, ExThera Medical Corporation, Aethlon Medical, Fresenius SE & 2021/10/19 09:09:22 OpenPR
A comprehensive overview of the Blood Purification Equipment market is recently added by UnivDatos Market Insights to its humongous database. The Blood Purification Equipment report has been aggregated by collecting informative data of various dynamics such as market drivers, restraints,
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs 2021/10/08 11:31:17 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS ) Bicycle Therapeutics plc (NASDAQ: BCYC ) (announced interim Phase 1 data for BT5528 and preliminary results from Phase 1 study of BT8009) Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX ) Cytokinetics, Incorporated (NASDAQ: CYTK ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) Legend Biotech Corporation (NASDAQ: LEGN ) Click here for accessing Benzinga''s FDA Calendar Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 7) Acutus Medical, Inc. (NASDAQ: AFIB ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Amgen Inc. (NASDAQ: AMGN ) ( announced neurodegenerative disease drug collaboration with Nuemora) Angion Biomedica Corp. (NASDAQ: ANGN ) Applied DNA Sciences, Inc. (NASDAQ: APDN ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) ARCA biopharma, Inc. (NASDAQ: ABIO ) Avenue Therapeutics, Inc.
Massive Growth in Disposable Hemoperfusion Market Set to Witness Huge Growth by 2027 | Biosun Pharmed, Jafron Biomedical, CytoSorbents Corporation 2021/09/15 09:36:12 OpenPR
Hemoperfusion may be a treatment technique during which large volumes of the patients blood are passed over an adsorbent substance so as to get rid of toxic substances from the blood. Adsorption may be a process during which molecules or